A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer-Reference-Cited by-同舟云学术

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

Published:2012-03-15 Issue:3 Volume:133 Page:1049-1056
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Carlson Robert W.,O’Neill Anne,Vidaurre Tatiana,Gomez Henry L.,Badve Sunil S.,Sledge George W.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-012-1997-5.pdf

Reference25 articles.

1. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29(1):117–125

2. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI (2004) Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib (‘Iressa’, ZD1839). Clin Exp Metastasis 21(3):201–212. doi: 10.1023%2FB%3ACLIN.0000037697.76011.1d

3. Kurebayashi J (2005) Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 56(Suppl 1):39–46. doi: 10.1007/s00280-005-0099-z

4. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10(17):5670–5676. doi: 10.1158/1078-0432.CCR-04-0110

5. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68(3):826–833. doi: 10.1158/0008-5472.CAN-07-2707

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. X-ray crystallography study and optimization of novel benzothiophene analogs as potent selective estrogen receptor covalent antagonists (SERCAs) with improved potency and safety profiles;Bioorganic Chemistry;2023-12

2. Tyrosine kinase inhibitors in breast cancer (Review);Experimental and Therapeutic Medicine;2021-12-03

3. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians;Critical Reviews in Oncology/Hematology;2021-01

4. Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer;Clinical and Translational Oncology;2020-02-12

5. CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer;Medicine;2019-01